Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Open-label, Efficacy and Safety Study of AR882 and XOI Co-administration in Participants With Uncontrolled Gout Who Have Previously Failed Uricase Treatment
This study will assess the effect of AR882 and XOI co-administration on sUA lowering as well as reducing tophus burden in the population that has failed uricase treatment (eg., pegloticase). Failed uricase treatment is defined as having an inherent intolerance, anaphylaxis, infusion reaction, antibody development, and/or at least one sUA level that rose to greater than 6 mg/dL while on therapy.
Age
18 - 85 years
Sex
ALL
Healthy Volunteers
No
Arthrosi Investigative Site (105)
Margate, Florida, United States
Arthrosi Investigative Site (102)
Miami, Florida, United States
Arthrosi Investigative Site (109)
Tampa, Florida, United States
Arthrosi Investigative Site (106)
Jackson, Mississippi, United States
Arthrosi Investigative Site (108)
Charlotte, North Carolina, United States
Arthrosi Investigative Site (103)
Duncansville, Pennsylvania, United States
Arthrosi Investigative Site (104)
West Lake Hills, Texas, United States
Arthrosi Investigative Site (107)
Bellevue, Washington, United States
Start Date
December 3, 2025
Primary Completion Date
July 1, 2026
Completion Date
January 1, 2027
Last Updated
March 2, 2026
25
ESTIMATED participants
AR882 75 mg
DRUG
XOI Low Dose
DRUG
XOI High Dose
DRUG
Lead Sponsor
Arthrosi Therapeutics
NCT07089875
NCT06310967
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03047369